Forbion’s Sander Slootweg looks back over the company’s most successful year so far, and looks ahead at likely market and therapy area trends for 2024.

CAR-T therapy-associated T-cell malignancies that the US FDA is investigating could make the treatments less attractive in autoimmune diseases than in oncology, but patients in both settings already accept some cancer risk with other available medicines.

China's research-based pharma companies reported mixed third-quarter results for their anti-PD-1 antibodies, BTK and PARP inhibitors amid broader challenges including an ongoing government-led anti-corruption campaign.

Topics in this latest Chinese-language podcast include the US approval of Chinese innovative drugs including Junshi’s anti-PD-1 antibody toripalimab, Sanofi’s deal with BioMap for AI-powered drug discovery, Chinese companies' third-quarter results and the Biden-Xi summit on the sidelines of APEC and its implications for bilateral regulatory dialog.